File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer

TitlePhase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer
Authors
KeywordsRadioimmunotherapy
Antibody
Clinical trial
Colon cancer
Issue Date2006
Citation
Cancer Biotherapy and Radiopharmaceuticals, 2006, v. 21, n. 3, p. 243-256 How to Cite?
AbstractPurpose: The primary aim of this study was to evaluate the biodistribution and toxicity of 131I-chimeric(ch) TNT-1/B monoclonal antibody (MAB), which binds to intracellular antigens of necrotic regions within tumors, in patients with advanced colon or colorectal cancer. The rationale for targeting areas of tumor necrosis is the observation that necrotic lesions are more abundant in cancer lesions than in surrounding tissues. Patients and Methods: Cohorts of patients with advanced colon or colorectal cancer were administered a one-time 30-60-minute intravenous (i.v.) infusion of 131I-ChTNT-1/B at doses ranging from 12.95 to 66.23 MBq/kg (0.35-1.79 mCi/kg). Results: The dose-limiting toxicity, experienced at 66.23 MBq/kg (1.79 mCi/kg) 131I-ChTNT-1/B MAB, was myelosuppression. Two (2) patients at the 66.23-MBq/kg (1.79 mCi/kg) dose level had both grade 3 thrombocytopenia and grade 3 neutropenia that persisted for at least 2 weeks but were reversible. The maximum tolerated dose was 58.09 MBq/kg (1.57 mCi/kg) 131I-chTNT-1/B MAB. Of the 21 patients, one developed a moderate human antichimeric antibody (HACA) response and 6 developed low HACA responses. Conclusions: The infusion of 131I-chTNT-1/B MAB was well tolerated, without significant nonhematological toxicity. No patient obtained a complete or partial response, based on tumor cross-product response criteria. Tumor localization was seen in patients with dose levels at, and exceeding, 50.23 MBq/kg (1.36 mCi/kg) 131I-chTNT-1/B MAB. © Mary Ann Liebert, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/198783
ISSN
2015 Impact Factor: 1.715
2015 SCImago Journal Rankings: 0.637
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorStreet, Hilary Hardy-
dc.contributor.authorGoris, Michael L.-
dc.contributor.authorFisher, George Albert-
dc.contributor.authorWessels, Barry W.-
dc.contributor.authorCho, Cheryl-
dc.contributor.authorHernández, Carmen A.-
dc.contributor.authorZhu, Hongyunjune-
dc.contributor.authorZhang, Yuxia-
dc.contributor.authorNangiana, Jasvinder Singh-
dc.contributor.authorShan, Joseph S.-
dc.contributor.authorRoberts, Karen C.-
dc.contributor.authorKnox, Susan J.-
dc.date.accessioned2014-07-09T03:42:15Z-
dc.date.available2014-07-09T03:42:15Z-
dc.date.issued2006-
dc.identifier.citationCancer Biotherapy and Radiopharmaceuticals, 2006, v. 21, n. 3, p. 243-256-
dc.identifier.issn1084-9785-
dc.identifier.urihttp://hdl.handle.net/10722/198783-
dc.description.abstractPurpose: The primary aim of this study was to evaluate the biodistribution and toxicity of 131I-chimeric(ch) TNT-1/B monoclonal antibody (MAB), which binds to intracellular antigens of necrotic regions within tumors, in patients with advanced colon or colorectal cancer. The rationale for targeting areas of tumor necrosis is the observation that necrotic lesions are more abundant in cancer lesions than in surrounding tissues. Patients and Methods: Cohorts of patients with advanced colon or colorectal cancer were administered a one-time 30-60-minute intravenous (i.v.) infusion of 131I-ChTNT-1/B at doses ranging from 12.95 to 66.23 MBq/kg (0.35-1.79 mCi/kg). Results: The dose-limiting toxicity, experienced at 66.23 MBq/kg (1.79 mCi/kg) 131I-ChTNT-1/B MAB, was myelosuppression. Two (2) patients at the 66.23-MBq/kg (1.79 mCi/kg) dose level had both grade 3 thrombocytopenia and grade 3 neutropenia that persisted for at least 2 weeks but were reversible. The maximum tolerated dose was 58.09 MBq/kg (1.57 mCi/kg) 131I-chTNT-1/B MAB. Of the 21 patients, one developed a moderate human antichimeric antibody (HACA) response and 6 developed low HACA responses. Conclusions: The infusion of 131I-chTNT-1/B MAB was well tolerated, without significant nonhematological toxicity. No patient obtained a complete or partial response, based on tumor cross-product response criteria. Tumor localization was seen in patients with dose levels at, and exceeding, 50.23 MBq/kg (1.36 mCi/kg) 131I-chTNT-1/B MAB. © Mary Ann Liebert, Inc.-
dc.languageeng-
dc.relation.ispartofCancer Biotherapy and Radiopharmaceuticals-
dc.subjectRadioimmunotherapy-
dc.subjectAntibody-
dc.subjectClinical trial-
dc.subjectColon cancer-
dc.titlePhase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1089/cbr.2006.21.243-
dc.identifier.pmid16918301-
dc.identifier.scopuseid_2-s2.0-33746381980-
dc.identifier.volume21-
dc.identifier.issue3-
dc.identifier.spage243-
dc.identifier.epage256-
dc.identifier.isiWOS:000239162600010-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats